Patent, Antitrust Case Over Generic Amrix Bifurcated
Mylan Inc., defendant in a patent infringement suit over its efforts to make a generic version of the drug Amrix, will not be able to raise antitrust counterclaims or a patent...To view the full article, register now.
Already a subscriber? Click here to view full article